Meinox Technologies is a health and wellness startup based in Turkey, founded in 2014. The company is focused on developing personalized therapeutics to combat cancer, with a particular emphasis on creating a library of first-in-class, selective small molecule inhibitors targeting oncogenic MEIS, PBX, TGIF2 proteins, and their co-factor HOXA9. These lead pre-clinical compounds are currently under investigation for the treatment of specific blood cancers.
There is no investment information
No recent news or press coverage available for Meinox Pharma Technologies.